Sign in Subscribe
Cancer

Molecular Characterization of Adeno-Associated Virus Integration Profiles

Strategic Insights

— 1 min read

Researchers from BioMarin Pharmaceutical Inc. have presented a molecular characterization of adeno-associated virus (AAV) integration profiles in human biopsy samples from valoctocogene roxaparvovec clinical trials and nonhuman primates (NHPs) treated with the same gene therapy. The study aimed to assess the integration profiles of the AAV vector, which is used in gene therapy for severe hemophilia A, to understand its safety and efficacy.

Key Takeaways:

  • The number of genomic integrations was significantly lower than the previously reported number of transgene-expressing cells, indicating a lower risk of off-target effects.
  • The integration profiles were similar between human and NHP samples, suggesting that preclinical assessments of AAV vector integration in NHPs are representative of outcomes in humans.
  • The integration profiles were polyclonal, evenly distributed across the genome, and demonstrated a bias toward regions of open chromatin and actively transcribed genes, with no relative enrichment in cancer-associated genes.
  • The research concluded that AAV vector integration profiles in NHPs are representative of outcomes in humans, providing valuable insights for the development and evaluation of gene therapies.
  • The study highlights the importance of understanding gene therapy mechanisms to ensure their safety and efficacy in humans.
  • BioMarin Pharmaceutical Inc. provided financial support for the research, and the study was peer-reviewed.
  • The research has significant implications for the development and approval of AAV-based gene therapies for various diseases.

Statistics:

  • The number of genomic integrations was substantially below 10 in the human biopsy samples.
  • The integration profiles were similar between human (5 samples) and NHP (5 samples) samples.
  • The bias toward regions of open chromatin and actively transcribed genes was observed in both human and NHP samples.
  • The study suggests that approximately 1 in 10 neutrophils exhibited a certain level of transgene expression in both human and NHP samples.

Sources:

  • Recombinant Adeno-associated Virus Integration Profiles In Nonhuman Primates and Gene Therapy Participants After Treatment With Valoctocogene Roxaparvovec. Human Gene Therapy, 2025.
  • BioMarin Pharmaceutical Inc. (105 Digital Dr, Novato, CA 94949, United States)
  • Chris B. Russell, BioMarin Pharmaceutical Inc.
  • Mary Ann Liebert, Inc (140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA)
  • Human Gene Therapy can be contacted at Mary Ann Liebert, Inc.

Read more